A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

NCT05438706 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Triple-negative Breast Cancer

Interventions

DRUG: chidamide
DRUG: camrelizumab
DRUG: carboplatin
DRUG: capecitabine

Sponsor

Fudan University